Diagnosis and Treatment Strategy of Recurrent Spontaneous Abortion Associated With Thrombophilla
Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Shanghai, China, 200051
- Recruiting
- Shanghai first Maternity and Infant health hospital, Tong Ji University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Woman who had their Second miscarriage before 12(th) week of gestation.The patient who is diagnosed as thrombophilia with recurrent pregnancy loss. Signed consent form.
Exclusion Criteria:
- having experiencedsevere allergies, trauma history and/or operation history within 3 months
- with a history of mental illness and/or family history of mental illness
- limb disabled
- taking medicine within one month
- suffering major events or having mood swings
- with a history of recurrent pregnancy loss
- having internal and surgical disease(after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine rotine)
- Chromosome aberrations in anyone of the couple.
- patients who have drug contraindications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: aspirin group
low dose aspirin, 75-100mg, bid, after pregnancy
|
|
|
EXPERIMENTAL: low molecular weight heparin group
low molecular weight heparin, 4100u, qd, after pregnancy
|
|
|
EXPERIMENTAL: combination group
low molecular weight heparin, 4100u, once a day and low dose aspirin, 75-100mg, bid.
After pregnancy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
D-Dimer
Time Frame: through study completion, an average of 3 year
|
through study completion, an average of 3 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
BMI in kg/m^2
Time Frame: through study completion, an average of 3 year
|
through study completion, an average of 3 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Hematologic Diseases
- Thrombophilia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Anticoagulants
- Aspirin
- Heparin
Other Study ID Numbers
Other Study ID Numbers
- ShanghaiFIMH-0002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.